<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173625</url>
  </required_header>
  <id_info>
    <org_study_id>AC-076-102</org_study_id>
    <nct_id>NCT03173625</nct_id>
  </id_info>
  <brief_title>A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body</brief_title>
  <official_title>Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of AC-076 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <brief_summary>
    <textblock>
      The main objective of the study is to investigate the safety and tolerability of single
      ascending doses of AC-076 administered as subcutaneous injection
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Actual">April 15, 2017</completion_date>
  <primary_completion_date type="Actual">April 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>From study treatment administration up to day 3</time_frame>
    <description>Treatment-emergent AEs and treatment-emergent serious AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in electrocardiogram (ECG) variables</measure>
    <time_frame>From study treatment administration up to day 3</time_frame>
    <description>ECG variables are to be recorded at rest using a standard 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in supine blood pressure</measure>
    <time_frame>From study treatment administration up to day 3</time_frame>
    <description>Supine blood pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in pulse rate</measure>
    <time_frame>From study treatment administration up to day 3</time_frame>
    <description>Pulse rate (bpm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of inhibition of platelet aggregation (IPA) using anticoagulant assays</measure>
    <time_frame>From baseline up to day 3</time_frame>
    <description>Maximum (MPA) and final (FPA) platelet aggregation using light transmission aggregometry (LTA) assay.
% inhibition of platelet aggregation (IPA), MPA and FPA.
P2Y12 reaction units (PRU) using the VerifyNow P2Y12 assay.
IPA PRU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of AC-076</measure>
    <time_frame>From baseline up to day 3</time_frame>
    <description>Cmax of AC-076 will be derived by non-compartmental analysis of the plasma concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach Cmax (tmax)</measure>
    <time_frame>From baseline up to day 3</time_frame>
    <description>tmax of AC-076 will be derived by non-compartmental analysis of the plasma concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal half-life (t1/2)</measure>
    <time_frame>From baseline up to day 3</time_frame>
    <description>t1/2 of AC-076 will be derived by non-compartmental analysis of the plasma concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curves during a dosing interval [AUC(0-t)] of</measure>
    <time_frame>From baseline up to day 3</time_frame>
    <description>AUC(0-t) of AC-076 will be derived by non-compartmental analysis of the plasma concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curves from time 0 to inf [AUC(0-inf)]</measure>
    <time_frame>From baseline up to day 3</time_frame>
    <description>AUC(0-inf) of AC-076 will be derived by non-compartmental analysis of the plasma concentration-time profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>AC-076 sc administration - single ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1, 48 subjects will receive AC-076 at different single dose levels in a sequential manner and in a maximum of 6 dose levels, starting from 1 mg. Subjects will be followed by an observation period of 48 h. Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For each AC-076 dose level tested, 2 healthy male subjects will receive matching placebo in the same condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-076 for s.c. administration</intervention_name>
    <description>Lyophilized AC-076A to be reconstituted with 1 mL of water for injection</description>
    <arm_group_label>AC-076 sc administration - single ascending dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile 0.9% w/v sodium chloride solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Body mass index (BMI) of 18.0 to 31.0 kg/m2 (inclusive) at screening

          -  Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg,
             and pulse rate 45-90 beats per minute (inclusive) at screening

          -  Healthy on the basis of physical examination, electrocardiogram and laboratory tests

          -  Maximum (at peak) platelet aggregation ≥ 40%

          -  Values of closure time tested with the Platelet Function Analyzer (PFA) equipment, for
             both cartridges of collagen/epinephrine and collagen/ADP below the upper limit of
             normal range at screening

        Exclusion Criteria:

          -  Known hypersensitivity to AC-076 or drugs of the same class, or any of their
             excipients

          -  Family or personal history of prolonged bleeding or bleeding disorders, intracranial
             vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic
             ulcers

          -  Platelet count &lt; 120 × 109 L-1 at screening

          -  Known platelet disorders

          -  Orthostatic hypotension at screening (i.e., decrease from supine to standing BP of &gt;
             20 mmHg in SBP or &gt; 10 mmHg in DBP after being in standing position for 3 min)

          -  Previous treatment with acetylsalicylate, non-steroidal anti-inflammatory drugs or any
             medication with blood thinning activity within 3 weeks prior to study drug
             administration; or with any other prescribed medications (including vaccines) or over
             the counter medications within 2 weeks prior to study drug administration

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Eric JUIF, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biotrial Inc.</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2017</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

